Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P05412 (
c-Jun
)
11,453
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Viral infection induces type I interferons (IFN-alpha and
IFN-beta
) that recruit unexposed cells in a self-amplifying response. We report that the transcription factor MafB thwarts auto-amplification by a metastable switch activity. MafB acted as a weak positive basal regulator of transcription at the IFNB1 promoter through activity at
transcription factor AP-1
-like sites. Interferon elicitors recruited the transcription factor IRF3 to the promoter, whereupon MafB acted as a transcriptional antagonist, impairing the interaction of coactivators with IRF3. Mathematical modeling supported the view that prepositioning of MafB on the promoter allows the system to respond rapidly to fluctuations in IRF3 activity. Higher expression of MafB in human pancreatic islet beta cells might increase cellular vulnerability to viral infections associated with the etiology of type 1 diabetes.
...
PMID:The transcription factor MafB antagonizes antiviral responses by blocking recruitment of coactivators to the transcription factor IRF3. 2064 78
LPS stimulation of macrophages production of
IFN-beta
plays a key role in innate immunity defending the microbial invasion. In this study, the effect of S632A3 promoting LPS-induced
IFN-beta
production and the underlying mechanism were investigated, mRNA level was measured by real-time PCR, cytokine production was determined by ELISA, GSK-3beta activity was investigated by kinase assay, protein phosphorylation and expression were evaluated by Western blotting. The results revealed that S632A3 significantly augmented
IFN-beta
production by LPS-stimulated macrophages. S632A3 inhibition of the activation of GSK-3beta, reduced the threonine 239 phosphorylation of transcription factor
c-Jun
but increased the total level of
c-Jun
in LPS-stimulated macrophages. Moreover, small interfering RNA-mediated knockdown of
c-Jun
level abrogated the ability of S632A3 to augment
IFN-beta
. The study thus demonstrates S632A3 being a new anti-inflammation lead compound and provides a molecular mechanism by which S632A3 promoted LPS-induced
IFN-beta
production in macrophages through inhibiting the activation of GSK-3beta.
...
PMID:[S632A3 promotes LPS-induced IFN-beta production through inhibiting the activation of GSK-3beta]. 2413 77
<< Previous
1
2
3